Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kaern

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Cancer Research|June 13, 2000
DNA copy number changes in malignant ovarian germ cell tumorsS M Kraggerud, J Szymanska, V M Abeler, et al.
British Journal of Cancer|July 28, 2012
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patientsU Wagner, C Marth, R Largillier, et al.
Lancet (London, England)|February 24, 2001
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinomaI Vergote, J De Brabanter, A Fyles, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatinG B Kristensen, I Vergote, G Stuart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 1999
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experienceC Tropé, T Hogberg, J Kaern, et al.
Journal of the National Cancer Institute|May 4, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year resultsM J Piccart, K Bertelsen, K James, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancerM J Piccart, K Bertelsen, G Stuart, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Cancer Research|June 13, 2000
DNA copy number changes in malignant ovarian germ cell tumorsS M Kraggerud, J Szymanska, V M Abeler, et al.
British Journal of Cancer|July 28, 2012
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patientsU Wagner, C Marth, R Largillier, et al.
Lancet (London, England)|February 24, 2001
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinomaI Vergote, J De Brabanter, A Fyles, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatinG B Kristensen, I Vergote, G Stuart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 1999
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experienceC Tropé, T Hogberg, J Kaern, et al.
Journal of the National Cancer Institute|May 4, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year resultsM J Piccart, K Bertelsen, K James, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancerM J Piccart, K Bertelsen, G Stuart, et al.
Pageof 7